With M&A activity showing signs of a potentially significant revival in 2024, David Elms, Head of Diversified Alternatives, and Julius Bird, Client Portfolio Manager, discuss what this could mean for investors allocating to alternatives.
Insights
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
How do you construct an absolute return strategy to stand the test of time?
With stock dispersion once again at the fore, offering greater potential for uncorrelated returns, is this ingredient that absolute return investors have been waiting for?
Could interest rates change the tune for publicly listed alternatives to follow in 2024?
Are higher interest rates opening the door to stock selection again in 2024?
David Elms argues why a changing market outlook in 2024 should prompt investors to consider a greater allocation to alternatives.
How can investors use the equity repo market as part of a balanced risk-adjusted allocation to alternatives?
What are the key considerations for constructing diversified Multi Strategy portfolios to help meet investors’ needs?
The Portfolio Construction and Strategy Team highlights the current opportunities within the public property sector.
Are listed alternatives pricing in the impact of central bank policy moves more accurately than more traditional assets?
While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.